Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.41 |
| ▸ | CYP11B2 | P19099 | 17/20 | 0.41 |
| ▸ | CYP11B1 | P15538 | 14/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3647016 | 0.83 | RAB9A (0.39) | POLBHCAR2CYP11B2CYP11B1CYP3A4 | |
| SCHEMBL2732538 | 0.82 | CYP1A2 (0.39) | POLBHCAR2CYP11B2CYP11B1CYP3A4 | |
| SCHEMBL433999 | 0.80 | CYP11B2 (0.44) | CYP11B2CYP11B1CYP19A1CYP2C9 | |
| SCHEMBL30559767 | 0.79 | CYP1A2 (0.39) | POLBHCAR2CYP11B2CYP11B1CYP3A4 | |
| SCHEMBL29252928 | 0.79 | CYP1A2 (0.39) | POLBHCAR2CYP11B2CYP11B1CYP3A4 | |
| SCHEMBL28777961 | 0.79 | CYP1A2 (0.39) | POLBHCAR2CYP11B2CYP11B1CYP3A4 | |
| SCHEMBL15474181 | 0.79 | CYP11B1 (0.37) | POLBHCAR2CYP11B2CYP11B1CYP3A4 | |
| SCHEMBL24534060 | 0.78 | CYP11B1 (0.42) | POLBHCAR2CYP11B2CYP11B1CYP3A4 | |
| SCHEMBL22795696 | 0.78 | POLB (0.41) | POLBHCAR2CYP11B2CYP11B1CYP19A1 | |
| SCHEMBL3507833 | 0.78 | CYP11B1 (0.42) | POLBHCAR2CYP11B2CYP11B1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 214 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260138978-A1 | POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M1 | VANDERBILT UNIV (US) | 2026-05-21 | — | — | US | disclosed |
| EP-4605089-A1 | COMPOUNDS USEFUL IN MODULATING EGFR AND PI3K | Mekanistic Therapeutics LLC (US) | 2025-08-27 | — | — | EP | disclosed |
| WO-2025101914-A1 | SUBSTITUTED AMINOBENZYL HETEROARYL COMPOUNDS AS EGFR AND/OR PI3K INHIBITORS HAVING IMPROVED THERAPEUTIC INDEX AGAINST SOLID TUMORS | MEKANISTIC THERAPEUTICS LLC (US) | 2025-05-15 | — | — | WO | disclosed |
| US-20250017914-A1 | 6-AZA-QUINOLINE DERIVATIVES AND RELATED USES | BLACK DIAMOND THERAPEUTICS, INC. | 2025-01-16 | — | — | US | disclosed |
| US-12187742-B2 | Dual ATM and DNA-PK inhibitors for use in anti-tumor therapy | XRAD THERAPEUTICS, INC. (US) | 2025-01-07 | — | — | US | disclosed |
| US-20240239764-A1 | SUBSTITUTED AMINOBENZYL HETEROARYL COMPOUNDS AS EGFR AND/OR PI3K INHIBITORS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2024-07-18 | — | — | US | disclosed |
| US-20240239764-A1 | SUBSTITUTED AMINOBENZYL HETEROARYL COMPOUNDS AS EGFR AND/OR PI3K INHIBITORS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2024-07-18 | — | — | US | disclosed |
| US-20240239764-A1 | SUBSTITUTED AMINOBENZYL HETEROARYL COMPOUNDS AS EGFR AND/OR PI3K INHIBITORS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2024-07-18 | — | — | US | disclosed |
| EP-4399210-A1 | 6-AZA-QUINOLINE DERIVATIVES AND RELATED USES | Black Diamond Therapeutics, Inc. (US) | 2024-07-17 | — | — | EP | disclosed |
| CN-118159537-A | 6-Aza-quinoline derivatives and related uses | 黑钻治疗公司 | 2024-06-07 | — | — | CN | disclosed |
| WO-2004045508-A2 | USE OF PDE4 INHIBITORS AS ADJUNCT THERAPY FOR PSYCHIATRIC DISORDERS | MERCK & CO., INC. (US) | 2004-06-03 | — | — | WO | disclosed |
| US-6743802-B2 | ASTHMA THERAPY; ANTIINFLAMMATORY AGENTS | MERCK FROSST CANADA & CO. (CA) | 2004-06-01 | — | — | US | disclosed |
| US-20040102472-A1 | Method of preparing inhibitors of phosphodiesterase-4 | MERCK & CO., INC. | 2004-05-27 | — | — | US | disclosed |
| EP-1397359-A1 | 1-BIARYL-1,8-NAPTHYRIDIN-4-ONE PHOSPHODIESTERASE-4 INHIBITORS | Merck Frosst Canada & Co. (CA) | 2004-03-17 | — | — | EP | disclosed |
| US-6677351-B2 | USEFUL IN TREATMENT OF ASTHMA AND INFLAMMATION | MERCK FROSST CANADA & CO. (CA) | 2004-01-13 | — | — | US | disclosed |
| WO-2004000814-A1 | 8-(BIARYL) QUINOLINE PDE4 INHIBITORS | MERCK FROSST CANADA & CO. (CA) | 2003-12-31 | — | — | WO | disclosed |
| US-20030114478-A1 | Alkyne-aryl phosphodiesterase-4 inhibitors | MERCK CANADA INC. (CA) | 2003-06-19 | — | — | US | disclosed |
| US-20030096829-A1 | 1-biaryl-1,8-naphthyridin-4-one phosphodiesterase-4 inhibitors | MERCK FROSST CANADA LTD. (CA) | 2003-05-22 | — | — | US | disclosed |
| WO-2003018579-A1 | ALKYNE-ARYL PHOSPHODIESTERASE-4 INHIBITORS | MERCK FROSST CANADA & CO. (CA) | 2003-03-06 | — | — | WO | disclosed |
| WO-2002094823-A1 | 1-BIARYL-1,8-NAPTHYRIDIN-4-ONE PHOSPHODIESTERASE-4 INHIBITORS | MERCK FROSST CANADA & CO. (CA) | 2002-11-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040102472-A1 | Method of preparing inhibitors of phosphodiesterase-4 | PDE4B, PDE4A, PDE5A | POLB 846/4885HCAR2 3472/4885CYP11B2 66/4885 |
| US-20030096829-A1 | 1-biaryl-1,8-naphthyridin-4-one phosphodiesterase-4 inhibitors | PDE4A, PDE4B, PDE7A | POLB 404/4885HCAR2 2258/4885CYP11B2 227/4885 |
| US-20240239764-A1 | SUBSTITUTED AMINOBENZYL HETEROARYL COMPOUNDS AS EGFR AND/OR PI3K INHIBITORS | EGFR, ERBB2, ERBB3 | POLB 521/4885HCAR2 4305/4885CYP11B2 2635/4885 |
| US-20030114478-A1 | Alkyne-aryl phosphodiesterase-4 inhibitors | PDE4A, PDE3B, PDE4B | POLB 2537/4885HCAR2 1012/4885CYP11B2 152/4885 |
| US-20250017914-A1 | 6-AZA-QUINOLINE DERIVATIVES AND RELATED USES | TOP2A, TOP2B, UGT2B7 | POLB 416/4885HCAR2 3300/4885CYP11B2 87/4885 |
| US-20260138978-A1 | POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M1 | CHRM1, CHRM4, CHRM2 | POLB 3104/4885HCAR2 439/4885CYP11B2 1716/4885 |
| US-12187742-B2 | Dual ATM and DNA-PK inhibitors for use in anti-tumor therapy | ATM, CHEK2, CHEK1 | POLB 27/4885HCAR2 4743/4885CYP11B2 2103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.